Syndax Stock Surges: UBS Boosts Price Target!

Wednesday, Jul 16, 2025 6:24 am ETnullmin read
SNDX--
Aime RobotAime Summary

- Syndax Pharmaceuticals' stock surged after UBS raised its price target.

- The investment bank increased its target to $12 from $8, citing positive clinical data for its lead drug candidate.

- Analysts highlighted the drug's potential in treating advanced cancers, driving market optimism.

- The move reflects growing confidence in Syndax's late-stage trial results and future commercial prospects.

Insightful stock picks for the savvy investor.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet